Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
This randomized phase I/II trial is studying gemcitabine hydrochloride and vismodegib to see
how well they work compared with gemcitabine hydrochloride alone in treating patients with
recurrent or metastatic pancreatic cancer. Drugs used in chemotherapy, such as gemcitabine
hydrochloride, work in different ways to stop the growth of tumor cells, either by killing
the cells or by stopping them from dividing. Vismodegib may slow the growth of tumor cells.
It is not yet known whether giving gemcitabine hydrochloride together with vismodegib is more
effective than gemcitabine hydrochloride alone in treating patients with pancreatic cancer.